IL-12 emerged as an attractive therapeutic target for CD, leading to the development of anti-interleukin inhibitors, such as UST, which has been categorized as anti–IL-12/IL­23 antibodies following the finding of IL­23 (17). This evidence concerns the gene IL23A and Cowden disease.